Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 188, Issue 1, Pages 129-146Publisher
WILEY
DOI: 10.1111/bjh.16355
Keywords
acute myeloid leukaemia; allogeneic stem cell transplantation; graft-versus-host disease; graft-versus-leukaemia
Categories
Funding
- CRUK
- Bloodwise
- Cure Leukaemia
- Birmingham ECMC Centre programme
Ask authors/readers for more resources
Acute myeloid leukaemia (AML) is the commonest indication for allogeneic stem cell transplantation (allo-SCT) worldwide. The accumulated experience of allografting in AML over the last four decades has provided critical insights into both the contribution of the conditioning regimen and the graft-versus-leukaemia effect to the curative potential of the most common form of immunotherapy utilised in standard clinical practice. Coupled with advances in donor availability and transplant technologies, this has resulted in allo-SCT becoming an important treatment modality for the majority of adults with high-risk AML. At the same time, advances in genomic classification, coupled with progress in the accurate quantification of measurable residual disease, have increased the precision with which allo-mandatory patients can be identified, whilst simultaneously permitting accurate identification of those patients who can be spared the toxicity of an allograft. Despite this progress, disease recurrence still remains a major cause of transplant failure and AML has served as a paradigm for the development of strategies to reduce the risk of relapse - notably the novel concept of post-transplant maintenance, utilising pharmacological or cellular therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available